Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Date:5/3/2011

THE WOODLANDS, Texas, May 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2011.  

"Our pipeline of first-in-class drugs continues to make significant progress.  Results from a mechanistic study of a tablet formulation of LX4211 in diabetes patients provided further confirmation of the drug's unique dual mechanism of action, and preparations to initiate a Phase 2b study of LX4211 in the second quarter are on track," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "In addition, we anticipate completing enrollment in the U.S. Phase 2a clinical trial of LX1032 in patients with carcinoid syndrome in the second quarter, with results expected shortly thereafter."

Key Progress in Clinical Pipeline

  • Lexicon reported data from a clinical trial and mechanistic study of a solid oral tablet formulation of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2, showing that LX4211 significantly increased GLP-1 (total and active) and PYY, important mediators of glycemic and appetite control.  The drug also produced rapid and significant improvement in post-prandial glucose (PPG) and fasting plasma glucose (FPG), consistent with results observed in the previously completed Phase 2a study of a liquid formulation of LX4211.  Pharmacokinetic and pharmacodynamic data from the study indicated that the solid oral formulation and the liquid formulation were comparable in key parameters of hormonal release, PP
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Lexicon to Provide First Quarter 2011 Financial Results
    2. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
    3. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    5. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
    6. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
    7. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
    8. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
    9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
    10. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
    11. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
    (Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
    (Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
    Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
    ... 14, 2011 Regulus Therapeutics Inc ., a ... medicines targeting microRNAs, today announced that it has added ... The addition of Dr. Hannon, a researcher whose work ... microRNA pathway, increases SAB membership to six pioneers in ...
    ... Renal Therapies Division of B. Braun Medical ... Plasmat™ Futura System for H.E.L.P. ®   LDL Apheresis ... therapy provides a more easy-to-use system for clinicians ... severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
    Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
    (Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
    (Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
    (Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
    (Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
    (Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
    Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
    ... or the "Company") (NASDAQ: TTHI , TSX: TTH) ... at 5:00 P.M. EST to discuss,the Second Quarter fiscal ... Officer of the Company, will host the call. Transition,will ... press release to,be issued prior to the call. In ...
    ... Florida biochemist says coral-killing ... synthetics harm humans, too, ORLANDO, Fla., Feb. ... Florida biochemist Celia Ferreira, Ph.D.,advises., Scientists have found a link ... sunscreen that wash off swimmers every,year., According to a study ...
    ... MedThink Communications, an,innovator in medical communications, brand ... by Salix Pharmaceuticals, Inc, in,Morrisville to launch ... an,orally disintegrating form of metoclopramide., Salix ... orally disintegrating,metoclopramide tablet and will bring the ...
    ... Statement of Matthew L.,Myers President, Campaign for Tobacco-Free ... will begin negotiations on an historic,international treaty to ... products -- a global problem that funds organized ... and,undermines efforts to reduce tobacco use and save ...
    ... play a key role in the likelihood their patients ... interventions targeting both the provider and the patient are ... particular must take into account patient barriers such as ... discovered. The study is published in the March 15, ...
    ... Web pages dedicated to disseminating breast cancer information, researchers ... have determined that while most breast cancer data found ... pages featured inaccuracies and sites displaying complementary and alternative ... or misleading health information. , Published in the ...
    Cached Medicine News:Health News:Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST 2Health News:Choose Biodegradable Sunscreen to Save Coral Reefs 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:U.S. on Sidelines as Nations Launch Negotiations on Treaty to Combat Smuggling, Counterfeiting and Other Illicit Trade in Tobacco Products 2Health News:U.S. on Sidelines as Nations Launch Negotiations on Treaty to Combat Smuggling, Counterfeiting and Other Illicit Trade in Tobacco Products 3Health News:Provider influence and patient barriers affect use of colorectal cancer screening 2Health News:Review of online breast cancer information encourages healthy skepticism for consumers 2
    Bruns bone curette, 9, oval, solid actagonal handle....
    MRI curette, 8.5" overall length....
    15" overall length, 5" handle....
    9.5" overall length, 4.5" handle....
    Medicine Products: